Y-Intercept (HK)’s Fulcrum Therapeutics FULC Stock Holding History

Y-Intercept (HK)’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Buy	681,832 +528,488	+345%	+$3.21M	0.05%	580
2026 Q1	$1.18M	Buy	153,344 +86,628	+130%	+$804K	0.02%	956
2025 Q4	$755K	Buy	66,716 +55,444	+492%	+$564K	0.02%	1103
2025 Q3	$104K	Buy	+11,272	New	+$81.6K	﹤0.01%	1489
2025 Q2	–	Sell	-32,086	Closed	-$92.4K	–	1757
2025 Q1	$92.4K	Buy	+32,086	New	+$118K	0.01%	1117
2024 Q4	–	Sell	-71,103	Closed	-$254K	–	1350
2024 Q3	$254K	Buy	+71,103	New	+$527K	0.02%	1076
2024 Q2	–	Sell	-54,416	Closed	-$514K	–	1554
2024 Q1	$514K	Buy	54,416 +37,998	+231%	+$339K	0.04%	697
2023 Q4	$111K	Buy	+16,418	New	+$72.8K	0.01%	1084
2023 Q3	–	Sell	-61,587	Closed	-$203K	–	1225
2023 Q2	$203K	Buy	61,587 +31,924	+108%	+$93.8K	0.02%	935
2023 Q1	$84.5K	Buy	+29,663	New	+$266K	0.01%	1070

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Y-Intercept (HK)'s FULC Position: Q2 2026 in Review

Y-Intercept (HK) increased its Fulcrum Therapeutics (FULC) stake by 345% in Q2 2026, buying an estimated $3.21M and bringing the position to 681,832 shares worth $2.5M. The position accounts for 0.05% of the portfolio, ranked #580.

Y-Intercept (HK) first reported a position in FULC in Q1 2023 and has held it in 10 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Y-Intercept (HK) held 681,832 shares of Fulcrum Therapeutics worth $2.5M as of Q2 2026.
Y-Intercept (HK) bought 528,488 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.21M.
Fulcrum Therapeutics made up 0.05% of Y-Intercept (HK)'s portfolio in Q2 2026, its #580 holding.
Y-Intercept (HK) first reported a position in Fulcrum Therapeutics in Q1 2023 and has held it in 10 quarters since.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.